Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Neurocrine Biosciences announced the publication of research in The Journal of Clinical Psychiatry that establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS) used with INGREZZA. The manuscript defines a minimal clinically important difference of four points for the TDIS total score, based on data from the KINECT clinical program including KINECT-3, KINECT-4, and KINECT-PRO.
Key figures
- Mcid tdis points
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.